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Needle Exchange Provision in COVID-19 Pandemic 
 
1. Background 
Harm reduction is a corner stone of our National Drug and Alcohol Strategy, ‘Reducing Harm, 
Supporting Recovery’ and one of the key elements of Harm Reduction among People who Inject 
Drugs (PWID) is the provision of needle exchange. In Ireland this service is delivered in a number of 
ways including fixed-site locations such as clinics or Community Pharmacies and novel interventions 
such as Backpacking Outreach programmes. 
2. Concerns 
 2.1 The virus causing COVID-19 spreads mainly from person-to-person, between people who 
are in close contact with one another, and through respiratory droplets produced when an infected 
person coughs or sneezes. The virus can also survive for relatively long periods of time on some 
surfaces. 
 2.2 Sharing injecting material increases the risk of infection with blood-borne viruses, such 
as HIV and viral hepatitis B and C, the sharing of inhalation, vaping, smoking or injecting equipment 
contaminated with COVID-19 may increase the risk of infection and play a role in the spread of the 
virus. 
 2.3 The COVID-19 outbreak may present additional risks that are currently not widely 
recognised, for example the sharing of cannabis joints, cigarettes, vaping or inhalation devices or 
drug paraphernalia.  
 2.4 Disruption to the supply of and access to equipment is likely to occur for a number of 
reasons that may include staff shortages, service disruption and closure, self-isolation and 
restrictions placed on free movement.  
3. Recommendations 
 3.1 A broader harm reduction approach in the current COVID-19 Pandemic needs to be 
considered by services when they deliver interventions. 
 3.2 Harm reduction advice should include information on the risk of COVID-19 transmission 
through all forms of intake, including sharing of cannabis joints, cigarettes, vaping and injecting 
equipment. 
 3.3 Contingency plans need to be developed to ensure continuity of provision of drug use 
paraphernalia. Scaling up the level of provision of equipment for individuals in self-isolation is likely 
to be necessary. 
 3.4 The utilisation and training of additional staff from section 39 agencies who are involved 
in the provision of care for PWUD should be considered to deal with staff shortages in CHO areas. 
The phone number of the harm reduction service should be available and circulated widely among 
the community targeted for injecting equipment.  
3. Process 
3.1 If an individual is in self-isolation and requires needle exchange, requests for equipment 
can be made by phone and amounts and equipment are pre-packed and then delivered to the 
specific location.  
3.2 The staff members must ensure that the intended target is in receipt of the package and 
that the package is not left unattended. 
3.3 At fixed site locations services, requests are taken over phone and also pre- packed and 
handed out at front door. 
3.4 All HSE staff and allied professionals delivering harm reduction services and injecting 
equipment should be provided with clear guidelines in relation to minimising contact with 
individuals, dealing with issues over the phone and maintaining personal safety.  
  
 
